{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:11:09Z","timestamp":1787170269577,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To quantitatively compare the incidence and symptom-specific risk of taxane-associated acute pain syndrome (TAPS) between nab-paclitaxel (nab-PTX) and paclitaxel (PTX) in adults with solid tumors, with pre-specified stratification by dosing frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase and Cochrane Library (to November 30, 2023) for randomised trials comparing nab-PTX versus PTX. After excluding docetaxel and other taxanes, nine head-to-head RCTs (3,699 patients) were pooled using random-effects models. Odds ratios (OR) and risk ratios (RR) were calculated for arthralgia and myalgia, with subgroup analyses by q3w, q4w and weekly schedules. Risk of bias was assessed with RoB 2.0 and publication bias by funnel plots and Egger\u2019s test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Myalgia incidence was significantly higher with nab-PTX (OR 1.25, 95% CI 1.06--1.48; I\u00b2 = 0%), whereas arthralgia did not differ (OR 1.07, 0.91\u20131.25; I\u00b2 = 0%). The excess myalgia was confined to the every-4-week (q4w, days 1,8,15) schedule (OR 1.32, 1.09\u20131.59; interaction p = 0.010), with no signal in q3w or weekly regimens. Up to one-quarter of q4w nab-PTX recipients experienced moderate-to-severe myalgia. Results were robust across sensitivity analyses and showed no publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Nab-PTX selectively increases acute myalgia risk by 25% versus PTX, exclusively within the q4w schedule, without affecting arthralgia. Dosing frequency, not cumulative dose, drives this symptom-specific toxicity. Clinicians should consider schedule selection and proactive analgesia when prescribing nab-PTX.\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                      , identifier CRD42023484814.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1650191","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:39:33Z","timestamp":1768372773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Nab-paclitaxel versus paclitaxel for taxane acute pain syndrome in solid tumors: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Lai","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Surgery, Affillated Hospital of Beihua University","place":["Jilin, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongBo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Jinhua People\u2019s Hospital","place":["Jinhua, ZheJiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiYong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Affillated Hospital of Beihua University","place":["Jilin, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e230122","DOI":"10.1001\/jamanetworkopen.2023.0122","article-title":"Effect of epirubicin plus paclitaxel vs epirubicin and cyclophosphamide followed by paclitaxel on disease-free survival among patients with operable ERBB2-negative and lymph node-positive breast cancer: A randomized clinical trial","volume":"6","author":"Yuan","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq315","article-title":"Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20\/99","volume":"22","author":"Albers","year":"2011","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0161","article-title":"Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial","volume":"20","author":"Zhao","year":"2023","journal-title":"Cancer Biol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01656","article-title":"Relacorilant + Nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: A three-arm, randomized, controlled, open-label phase II study","volume":"41","author":"Colombo","year":"2023","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3747\/co.v17i2.408","article-title":"Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey","volume":"17","author":"Saibil","year":"2010","journal-title":"Curr Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10040761","article-title":"Coping strategies, pain, and quality of life in patients with breast cancer","volume":"10","author":"O\u015bmia\u0142owska","year":"2021","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8099","article-title":"Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1","volume":"29","author":"Loprinzi","year":"2011","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3215-3","article-title":"Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review","volume":"24","author":"Fernandes","year":"2016","journal-title":"Support Care Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.065","article-title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","volume":"32","author":"Brufsky","year":"2021","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial","volume":"2","author":"Shitara","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2\/HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial: A randomized phase 3 clinical trial","volume":"4","author":"Gianni","year":"2018","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4598-7","article-title":"Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis","volume":"27","author":"Kanbayashi","year":"2019","journal-title":"Support Care Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1678-9","article-title":"Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer","volume":"130","author":"Pippen","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3927","article-title":"Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial","volume":"6","author":"Sridhar","year":"2020","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2010.01298.x","article-title":"Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer","volume":"6","author":"Guan","year":"2010","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5298","article-title":"Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502\/NCCTG N063H (Alliance)","volume":"33","author":"Rugo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12990-015-0008-5","article-title":"Paclitaxel induces acute pain via directly activating toll like receptor 4","volume":"11","author":"Yan","year":"2015","journal-title":"Mol Pain"},{"key":"B21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/PPO.0b013e31815a01f4","article-title":"The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism","volume":"13","author":"Loprinzi","year":"2007","journal-title":"Cancer J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27518","article-title":"Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1","volume":"118","author":"Reeves","year":"2012","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00520-023-07789-7","article-title":"Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment","volume":"31","author":"Saito","year":"2023","journal-title":"Support Care Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1650191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:39:39Z","timestamp":1771911579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1650191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1650191"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1650191","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1650191"}}